Owen L Woodman Selected Research

3-hydroxyflavone

1/2022	NP202 treatment improves left ventricular systolic function and attenuates pathological remodelling following chronic myocardial infarction.
5/2014	The flavonols quercetin and 3',4'-dihydroxyflavonol reduce platelet function and delay thrombus formation in a model of type 1 diabetes.
1/2013	Inhibition of platelet-mediated arterial thrombosis and platelet granule exocytosis by 3',4'-dihydroxyflavonol and quercetin.
5/2011	Cardioprotection from ischaemia-reperfusion injury by a novel flavonol that reduces activation of p38 MAPK.
10/2008	Discovery of water-soluble antioxidant flavonols without vasorelaxant activity.
4/2008	Using behaviour to predict stroke severity in conscious rats: post-stroke treatment with 3', 4'-dihydroxyflavonol improves recovery.
3/2008	Understanding the cardioprotective effects of flavonols: discovery of relaxant flavonols without antioxidant activity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Owen L Woodman Research Topics

Disease

15	Reperfusion Injury 01/2018 - 12/2003
8	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 09/2005
8	Ischemia 01/2018 - 01/2003
6	Myocardial Ischemia (Ischemic Heart Diseases) 01/2018 - 03/2008
5	Infarction (Infarctions) 07/2015 - 06/2004
4	Inflammation (Inflammations) 02/2020 - 05/2011
4	Hyperglycemia 01/2020 - 01/2011
4	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2019 - 04/2008
3	Myocardial Infarction 01/2022 - 07/2015
3	Type 2 Diabetes Mellitus (MODY) 01/2019 - 06/2011
3	Hypertension (High Blood Pressure) 07/2010 - 01/2007
3	Stroke (Strokes) 04/2008 - 07/2004
2	Left Ventricular Dysfunction 01/2022 - 01/2011
2	Diabetes Mellitus 01/2020 - 02/2011
2	Myocardial Reperfusion Injury 01/2018 - 01/2017
2	Obesity 01/2017 - 01/2016
2	Vascular Diseases (Vascular Disease) 01/2016 - 04/2007
2	Thrombosis (Thrombus) 05/2014 - 01/2013
2	Hypertrophy 01/2011 - 10/2006
1	Atherosclerotic Plaque (Atheroma) 01/2022
1	Body Weight (Weight, Body) 01/2020
1	Vascular System Injuries 01/2018
1	Memory Disorders (Memory Loss) 01/2017
1	Weight Gain 01/2017
1	Cognitive Dysfunction 01/2017
1	Heart Failure 02/2016
1	Carotid Artery Thrombosis 05/2014
1	Glucose Intolerance 03/2013
1	Hypoxia (Hypoxemia) 09/2011
1	Fibrosis (Cirrhosis) 01/2011
1	Coronary Artery Disease (Coronary Atherosclerosis) 09/2010
1	Cardiomegaly (Heart Hypertrophy) 07/2010

Drug/Important Bio-Agent (IBA)

13	AntioxidantsIBA 01/2019 - 12/2003
12	3',4'-dihydroxyflavonolIBA 01/2018 - 06/2004
11	FlavonolsIBA 01/2018 - 11/2004
7	3-hydroxyflavoneIBA 01/2022 - 03/2008
5	Superoxides (Superoxide)IBA 01/2020 - 06/2004
5	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2020 - 12/2003
4	Vasodilator Agents (Vasodilators)IBA 09/2011 - 11/2004
3	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2017 - 11/2009
3	IsoflavonesIBA 04/2012 - 07/2004
2	Blood Glucose (Blood Sugar)IBA 01/2020 - 06/2015
2	Streptozocin (Streptozotocin)FDA Link 01/2019 - 04/2008
2	Phosphotransferases (Kinase)IBA 01/2018 - 07/2015
2	Protein Kinases (Protein Kinase)IBA 01/2018 - 05/2011
2	Angiotensin IIIBA 10/2017 - 04/2007
2	Hydrogen Sulfide (Sulfide, Hydrogen)IBA 01/2017 - 10/2013
2	ProdrugsIBA 07/2015 - 12/2013
2	QuercetinIBA 05/2014 - 01/2013
2	p38 Mitogen-Activated Protein KinasesIBA 12/2013 - 05/2011
2	Glucose (Dextrose)FDA LinkGeneric 03/2013 - 01/2003
2	ResveratrolIBA 09/2010 - 01/2007
2	EquolIBA 04/2007 - 01/2007
2	daidzeinIBA 04/2007 - 07/2004
2	Nitroprusside (Sodium Nitroprusside)FDA LinkGeneric 01/2006 - 12/2003
1	LipoxinsIBA 02/2020
1	lipoxin A4IBA 02/2020
1	nitroxylIBA 01/2020
1	salicylhydroxamic acid (SHAM)IBA 01/2020
1	glimepiride (Amarel)FDA LinkGeneric 01/2019
1	LinagliptinIBA 01/2019
1	VildagliptinIBA 01/2019
1	Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA 01/2019
1	FlavonesIBA 01/2018
1	Calcium-Calmodulin-Dependent Protein Kinase Type 2IBA 01/2018
1	phospholambanIBA 01/2018
1	Taurine FDA Link 10/2017
1	ursodoxicoltaurineIBA 10/2017
1	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 10/2017
1	Vasoconstrictor AgentsIBA 10/2017
1	Adenosine (Adenocard)FDA LinkGeneric 01/2017
1	Mitochondrial Permeability Transition PoreIBA 01/2017
1	SugarsIBA 01/2017
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2017
1	Dopamine (Intropin)FDA LinkGeneric 01/2017
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2017
1	CalciumIBA 01/2017
1	Opioid Analgesics (Opioids)IBA 01/2017
1	IncretinsIBA 01/2017
1	oxyhyponitriteIBA 02/2016
1	Dobutamine FDA LinkGeneric 02/2016
1	TocominIBA 01/2016
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 07/2015
1	2- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- oneIBA 07/2015
1	2- (2- amino- 3- methoxyphenyl)- 4H- 1- benzopyran- 4- oneIBA 07/2015
1	ferric chlorideIBA 05/2014
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 12/2013
1	JNK Mitogen-Activated Protein KinasesIBA 12/2013
1	Insulin (Novolin)FDA Link 03/2013
1	FlavonoidsIBA 01/2013
1	Dimethyl Sulfoxide (DMSO)FDA LinkGeneric 10/2011
1	Cardiotonic Agents (Cardiac Stimulants)IBA 09/2011
1	Mitogen-Activated Protein KinasesIBA 05/2011
1	Glucagon-Like Peptide-1 ReceptorIBA 02/2011
1	CollagenIBA 01/2011
1	FructoseIBA 07/2010

Therapy/Procedure

8	Therapeutics 01/2022 - 07/2004
2	Thrombolytic Therapy 09/2011 - 11/2004
1	Surgical Amputation (Amputations) 01/2022
1	Drug Therapy (Chemotherapy) 02/2016